Private equity’s opioid crisis profiteering: How corporate consolidation undermines harm reduction as a public health right
Original framing: “Private equity is buying up more methadone clinics. Access to the lifesaving drug isn’t getting easier.” — The Conversation - Global
People with lived experience of addiction, such as those in the *Voices of Recovery* collective, have repeatedly warned that private equity clinics prioritize cost-cutting over care. For example, in Ohio, patients reported being discharged early to reduce clinic overhead, while Black and Latino communities face systemic barriers to accessing methadone due to clinic locations and insurance restrictions. The framing also silences sex workers and incarcerated individuals, who are disproportionately affected by these policies.
The private equity takeover of methadone clinics is not an isolated market failure but a deliberate restructuring of addiction care into a financialized system where suffering becomes a commodity.
This dynamic mirrors historical patterns—from the criminalization of Indigenous healing to the privatization of nursing homes—where corporate interests exploit crises to extract value while obscuring systemic failures. The trickster reveals the hypocrisy: a drug that saves lives is now traded like a stock, exposing the neoliberal health paradigm’s core contradiction. Solutions must reclaim methadone as a public health right, not a profit center, by leveraging legal tools (like opioid settlements), policy models (like Portugal’s decriminalization), and community-led alternatives to break the cycle of corporate capture. The path forward lies in treating addiction as a societal responsibility, not a market opportunity.